Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000791155 | SCV000930429 | uncertain significance | Myopathy, centronuclear, 5 | 2019-04-27 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001310771 | SCV001500705 | uncertain significance | not provided | 2021-01-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001310771 | SCV002446866 | benign | not provided | 2024-01-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002535832 | SCV003681805 | uncertain significance | Inborn genetic diseases | 2022-12-28 | criteria provided, single submitter | clinical testing | The c.7262C>T (p.P2421L) alteration is located in exon 30 (coding exon 30) of the SPEG gene. This alteration results from a C to T substitution at nucleotide position 7262, causing the proline (P) at amino acid position 2421 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003918270 | SCV004737107 | likely benign | SPEG-related disorder | 2019-11-14 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |